Observational study of patients with fibrosing interstitial lung disease in intensive care for respiratory failure

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, multicenter study focuses on patients with fibrosing interstitial lung diseases (ILD) who are admitted to intensive care units (ICUs) due to acute respiratory failure (ARF). The study aims to assess 6-month survival rates following ICU admission and identify prognostic factors for mortality. It also seeks to characterize ICU and hospital mortality rates, addressing the clinical challenges faced in managing these patients. The study highlights the severe complications associated with ILD and the need for evidence-based guidance in their treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Hospitalization in intensive care for acute respiratory failure
2. Requirement for standard oxygen therapy with an O2 flow rate \> 6 l/min, high-flow oxygen therapy, or mechanical ventilation (non-invasive or invasive)
3. Age ≥ 18 years
4. Patient (male or female) with chronic interstitial lung disease (ILD)

   1. Diagnosis of chronic ILD confirmed by a multidisciplinary discussion (MDD) prior to admission to intensive care, or
   2. Diagnosis of chronic ILD made during the intensive care stay due to the acute episode and confirmed by an expert opinion.

Exclusion Criteria:

1. Patient under legal guardianship or with restricted freedom
2. Patient hospitalized for psychiatric reasons or with a severe psychiatric illness causing a disability, subject to legal protection measures
3. Pregnant woman
4. Patient already enrolled in the study

Where it's running

• Hôpital Avicenne APHP Réanimation médico-chirurgicale
  Bobigny, France Recruiting

Study contacts

• Study coordinator: Nathan EBSTEIN, Dr
• Email: nathan.ebstein@aphp.fr
• Phone: 01 48 95 22 80

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nerandomilast in children with fibrosing ILD: tolerability and potential benefit

  This study tests whether nerandomilast is safe, tolerable, and helpful for children and teens with fibrosing interstitial lung disease.

  Recruiting at 26 sites Phase 3 Boehringer Ingelheim · Los Angeles, California and 46 other locations · NCT07366034

• Telitacicept for primary Sjögren’s with interstitial lung disease

  This study tests whether Telitacicept helps people with primary Sjögren’s syndrome and interstitial lung disease compared with standard immunosuppressants.

  Recruiting Peking University People's Hospital · Beijing · NCT07843381

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

• Treprostinil Palmitil Inhalation Powder for Progressive Pulmonary Fibrosis

  A 52-week study will test whether once-daily Treprostinil Palmitil Inhalation Powder helps lung function in adults with progressive pulmonary fibrosis compared to placebo.

  Recruiting Phase 3 Insmed Incorporated · DuBois, Pennsylvania · NCT07805785

• Treatment Response in Myositis-Associated RP-ILD in Adults

  This study tests how people with myositis and rapidly progressing interstitial lung disease respond to an immunosuppressant treatment approach.

  Recruiting Singapore General Hospital · Singapore · NCT07775235

• AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT

  This study tests how well the AccuPulmo CT Portal can identify pulmonary fibrosis on existing chest CT scans from adults at Taichung Veterans General Hospital.

  Recruiting Taichung Veterans General Hospital · Taichung · NCT07761377

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.